Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 304

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

Former Vancouver Firefighter Declares Psychedelic Drug Saved His Life

Somerville, Massachusetts, Passes Measure to Decriminalize Psychedelics

You Don’t Have to Take Psychedelics to Benefit from Them —...

PTSF 44 (with Colin Thompson, director of “Light Years”)

PT228 – Deborah Snyder from Synergetic Press

PTSF 43

PT227- Dr. Anne Wagner – Couples Therapy, MDMA, and MAPS

PTSF 42

PT226 – Veronika Gold & Harvey Schwartz from Polaris Insight Center

PTSF 45

Load more

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©